Coronary Microvascular Disease: the Next Frontier in Ischemic Heart Disease

Marie Guerraty, MD, PhD, is currently an instructor in cardiovascular medicine ‪@pennmedicine‬. Objectives: 1. Understand why Coronary Microvascular Disease (CMVD) is an important and prevalent clinical entity. 2. Draw from existing genomic and developmental research to gain insight into CMVD. 3. Understand how transcriptional coregulator Friend of GATA 2 (FOG2) may play a role in CMVD. Follow Yale Cardiovascular Medicine on Twitter:   / yalecardiology   Sign up for email updates: https://subscribe.yale.edu/ 0:00 Introduction 2:24 Coronary Arterial Circulation 7:23 CAD GWAS = Ischemic Heart Disease GWAS 12:32 Phenome-Wide Association Study of non 15:26 Discrete left heart catheterization 16:44 Matched cohorts for deeper phenotypic 24:34 Using CRISPR/Cas9 genome 27:08 Angiogenic effects of 33:37 TWIST1 in Smooth Muscle Cells 38:00 TWIST1 Summary 46:40 Acknowledgements